Biologic DMARDs (bDMARDs) confer a protective effect in patients with rheumatoid arthritis, lowering risk of developing sepsis as well as reducing mortality after serious infection and sepsis, according to results from a German registry presented at the 2015 ACR/ARHP Annual Meeting.
ACR/ARHP Annual Meeting 2015
Adding methotrexate (MTX) to golimumab (GLM) therapy might significantly improve some symptoms among patients diagnosed with psoriatic arthritis (PsA), suggests a study reported at the 2015 ACR/ARHP Annual Meeting.
Longer-term efficacy and safety data from the Phase 3 PALACE 1 study have confirmed that apremilast continues to demonstrate sustained and clinically meaningful improvements in psoriatic arthritis signs and symptoms at 3 years in patients who remained on the treatment, investigators concluded at the 2015 ACR/ARHP Annual Meeting.
The safety and tolerability of pregabalin for the treatment of fibromyalgia-associated pain does not differ by baseline pain severity, a pooled analysis of five phase 3 clinical trials presented at the 2015 ACR/ARHP Annual Meeting has shown.
Phosphodiesterase 5 (PDE5) inhibitors appear to be effective in treating Raynaud’s phenomenon secondary to scleroderma, investigators concluded at the 2015 ACR/ARHP Annual Meeting.
Golimumab was well tolerated and effective in reducing symptom severity and improving disease outcomes in patients with ankylosing spondylitis over 12 months, a Canadian longitudinal study reported at the 2015 ACR/ARHP Annual Meeting.
Treatment with tabalumab did not significantly affect serum creatinine, glomerular filtration rate, or urine protein/creatinine ratio over 52 weeks vs. placebo, investigators reported at the 2015 ACR/ARHP Annual Meeting.
Data presented at the 2015 ACR/ARHP Annual Meeting showed that patients with active nonradiographic axial spondyloarthritis who received golimumab showed greater improvement in quality of life and work productivity outcomes than placebo.
Patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) who develop hypersensitivity reactions to infliximab, etanercept and adalimumab are more likely to have positive skin tests despite the absence of an overall relationship with antidrug antibody (ADA) levels, according to a study reported at the 2015 ACR/ARHP Annual Meeting.
Dietary omega-3 fatty acid-rich fish consumption, but not omega-3 supplements alone, confer a protective effect against recurrent gout attacks, reported MaryAnn Zhang, MD, from the Boston University School of Medicine, Boston, MA, at the 2015 ACR/ARHP Annual Meeting.
- Loading...
Want to read more?
Please login or register first to view this content.
